• PDF: Delivered by email usually within 4 to 8 UK business hours.

Antibacterial Drugs: Commercial Prospects 2011-2026

  • Publication Date:January 2011
  • Publisher:Visiongain
  • Product Type: Report
  • Pages:1
  • ISBN:409090

Antibacterial Drugs: Commercial Prospects 2011-2026

What will this decade hold for that industry and market?

How will the antibacterial drug sector develop from 2011, and where can you find opportunities there? We show you prospects for revenue generation in human antibiotic medicine. You can order our report now, staying ahead. 

What revenues will the world antibacterial drug market yield from 2011 to 2026? What will be the revenue prospects for leading antibacterial products? What will be the sales trends for leading national markets, developed and developing?

Our report answers those questions and others. You will find original sales forecasts for 2010 to 2026. 

This new study focuses on antibacterial classes and the leading drugs there. We predict revenues and market opportunities for:
• Cephalosporins
• Fluoroquinolones
• Penicillins
• Macrolides
• Carbapenems.

Anti-infective treatments are a top 10 area of pharma research. We show how you can benefit from the antimicrobial drug sector's developments and opportunities from 2011.

You will find out how companies can make gains in antibacterial drugs, letting you assess the potential of the sector. You will find data, analyses and opinion to benefit your research, analysis, meetings and presentations.

Our report shows you present and future trends to watch. Novel and generic drug producers can benefit. We discovered which market areas have the strongest potential for growth and the most-promising research and development.

You will discover commercial prospects at total world, sub-market, product and national levels. You can assess the potential of the antibacterial drug industry and market now.

Analysis and expert opinion to aid your work - so you won't be left behind

Our new report provides you with revenue forecasts, market share analyses, SWOT analysis, an R&D review and expert opinion. That way, you can assess strengths, limitations, opportunities and threats in the antibacterial drug sector.

We include 53 tables and figures and two expert interviews (shown in the accompanying lists). You can stay ahead by ordering our report today. We aim to benefit your analyses and ideas, saving you time as well. 

Antibacterial Drugs: Commercial Prospects 2011-2026 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:
• You will receive hard data for the antibacterial drug sector - especially our revenue forecasts - helping you to stay ahead
• You will discover sales trends for the overall market and its main components from 2009 to 2026 - showing you where commercial potential will occur
• You will see the revenue prospects for leading products from 2009 to 2026, with discussion of market potential and competition for antibiotic sales
• You will find revenue prospects for leading national markets from 2009 to 2026 (US, Japan, UK, Germany, France, Spain, Italy, Brazil, China and India)
• You will investigate competition and opportunities influencing the antibacterial drug sector from 2011 onwards
• You will see what stimulates and restrains the antibiotics industry and market
• You will review product development, assessing the potential of R&D
• You will investigate commercial needs - some unmet - with therapeutic needs and commercial opportunities discussed
• You will analyse opportunities for established companies and those seeking to enter the market
• You will view expert opinion from our survey, including full interview transcripts.

That combination of qualitative and quantitative market analysis sets our reports apart.

You can order our report, giving you market information you need

Our report can benefit everybody interested in the antibacterial drug industry and market. You will see where the sector is heading, assessing the opportunities, needs and challenges there.

You will find answers and trends - we aim to save you time and aid your decisions. Order our report now, making sure you don't miss out. Please let us help your work.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs.
 
Table of Contents
1. Executive Summary
1.1 Antibacterials Market Review
1.2 Antibacterial Agents: Market Overview, 2011-2026 
1.2.1 Why is the Antibacterial R&D Pipeline Challenged?
1.2.2 Lessons for Companies Seeking to Enter the Market
1.2.3 Generic Competition
1.3 Aims, Scope and Format of Report
1.4 Research Methods

2. Bacterial Infections and their Treatments
2.1 An Introduction to Bacteria
2.1.1 Overview
2.1.2 Spectrum of Bacterial Activity
2.2 Bacterial Infections
2.2.1 Causes of Bacterial Infections
2.2.2 Mechanisms of Bacterial Action
2.2.3 Clinically-Important Bacteria
2.3 A Brief History of Antibacterial Agents
2.3.1 Discovery of Sulphonamides
2.3.2 Discovery of Penicillin
2.3.3 Other Milestones in the History of Antibacterial Agents
2.4 Principal Mechanisms of Antibacterial Action

3. World Market for Antibacterial Agents, 2011-2026
3.1 World Antibacterials Market Forecast, 2011-2026
3.2 Cephalosporins Will Continue to Play an Important Role in the Global Antibacterials Market
3.3 Market Forecast for Fluoroquinolone, Penicillin, Macrolide and Carbapenem Classes
3.4 The Antibacterials Market Remains Fragmented
3.5 Patent Expiries Will Slow Revenue Growth Rates
3.6 Few Antibacterial Agents Will Achieve Blockbuster Status in the Future?

4. World Market for Cephalosporins, 2011-2026
4.1 Overview
4.2 Cephalosporins will Decline in Sales as a Result of Patent Expiries
4.3 Rocephin (ceftriaxone) Leads the World Market for Cephalosporins
4.4 Flomox (cefcapene pivoxil) and Zinnat (cefuroxime axetil) are Strong Competitors to Rocephin (ceftriaxone) 
4.4.1 Market Forecast for Flomox (cefcapene pivoxil)
4.4.2 Market Forecast for Zinnat (cefuroxime axetil)
4.5 Meiact (ceftidoren pivoxil) Market Forecast
4.6 Fortum (ceftazidime) Market Forecast

5. World Market for Broad-Spectrum Penicillins, 2011-2026
5.1 Tazocin (Zosyn; tazobactam/piperacillin) is the Market Leader for Penicillins
5.2 Will GSK's Augmentin (amoxicillin) Overcome Generic Competition?
5.3 Pfizer's Unasyn (sulbactam and ampicillin) Stays in the Top Three, But for How Long?

6. World Market for Fluoroquinolones, 2011-2026
6.1 Overview
6.2 Increased Generic Competition will Lead to Reduced Sales of Fluoroquinolones
6.3 Fluoroquinolones Linked with Side Effects
6.4 Will Sales of J&J's Levaquin (levofloxacin) Still Dominate the Fluoroquinolones Market after Patent Expiry?
6.5 Levaquin (levofloxacin) Approved for Urinary Tract Infections and Acute Pyelonephritis
6.6 Market Share of Avelox (moxifloxacin hydrochloride) Expected to Grow Until 2015
6.7 Studies Reveal Avelox (moxifloxacin hydrochloride) to be Effective in Patients with CAP
6.8 On Rare Avelox Side Effects 
6.9 Sales of Cravit (levofloxacin) Expected to Decline?

7. World Market for Macrolides, 2011-2026
7.1 Overview
7.2 Klacid (clarithromycin) is the Market Leader for Macrolides
7.3 Zithromax (azithromycin) is Likely to Experience Negative Growth
7.4 Dalacin C (clindamycin) is Among the Top-Selling Macrolides

8. World Market for Carbapenems, 2011-2026
8.1 Overview
8.2 Merrem (meropenem) Continues to Lead the Market 
8.3 Zienam (imipenem + cilastatin) is the Second-Highest Selling Drug in the Carbapenem Class
8.4 Strong Growth Expected for Invanz (ertapenem)

9. Leading National Markets for Antibacterial Agents, 2011-2026
9.1 Leading Countries for Sales of Antibacterial Agents
9.2 Sales Forecasts for the Ten Leading National Markets, 2011-2026
9.2.1 The Antibacterials Market in the US, 2011-2026
9.2.2 The Antibacterials Market in China, 2011-2026
9.2.3 The Antibacterials Market in Japan, 2011-2026
9.2.4 The Indian Antibacterials Market, 2011-2026
9.2.5 The European Antibacterials Market, 2011-2026
9.2.6 The Brazilian Antibacterials Market, 2011-2026

10. Analysis of Factors That Influence the Antibacterials Market
10.1 SWOT Analysis of the Market
10.2 Drivers for and Restraints on Market Growth
10.2.1 Market Drivers
10.2.2 Market Restraints
10.3 Life Cycle Management Strategies Will Become Increasingly Important
10.4 Concerns over Antibacterial Drug Use
10.5 Comparative Studies of Antibacterial Agents
10.5.1 Advantages of Comparative Studies
10.5.2 Disadvantages of Comparative Studies 
10.6 Antibacterial Infections in Developing Countries
10.6.1 Unmet Medical Needs in Developing Countries
10.6.2 What are the Consequences of an Under-Regulated Antibacterials Market in Developing Countries?
10.6.3 Spread of Bacterial Resistance in Developing Countries
10.7 Antibacterial Infections in Developed Countries
10.7.1 Hospital-Acquired Infections
10.7.2 Which Common Pathogens Cause Hospital-Acquired Infections?
10.7.3 What are the Therapies for Treating Hospital-Acquired Infections?

11. Research Interviews
11.1 Interview with Dr Alexander O'Neill, Leeds University, UK
11.1.1 Unmet Needs
11.1.2 Research and Development
11.1.3 The Antibacterials Pipeline
11.1.4 Market Drivers
11.2 Interview with Professor Steven Firestine, Wayne State University, US
11.2.1 Unmet Needs
11.2.2 Research and Development
11.2.3 Outlook for the Antibacterials Market
11.2.4 The Antibacterials Pipeline

12. The Antibacterials R&D Pipeline
12.1 Obstacles to Stimulating the Antibacterials Pipeline 
12.2 Proposals for Stimulating the Global Antibacterials Pipeline
12.3 Cephalosporins Pipeline 
12.3.1 Ceftaroline
12.3.2 Ceftobiprole
12.3.3 CAZ 104
12.4 Lipoglycopeptides Pipeline
12.4.1 Dalbavancin
12.4.2 Ramoplanin
12.5 Iclaprim

13. Conclusions
13.1 The Antibacterials Market Enters a Period of Uncertainty 
13.1.1 Market Overview
13.1.2 Advice for Companies Seeking to Enter the Market
13.2 Global Revenues of Leading Antibacterial Agents
13.3 Combating the Effects of Bacterial Resistance and Stimulating a Weak Antibacterial R&D Pipeline
13.4 Opportunities in the Antibacterials Market
13.4.1 Antibacterials with Novel Mechanisms of Action 
13.4.2 Generic Companies versus Originator Pharmaceutical Companies
13.4.3 Market Outlook
13.5 The Future of the Antibacterials Market - Closing Comments

List of Tables

Table 2.1 Examples of Clinically-Important Bacteria
Table 2.2 Antibiotic Action by Drug Class
Table 3.1 Antibacterial Market Shares ($m, %) by Drug Class, 2011-2019
Table 3.2 Antibacterial Market Shares ($m, %) by Drug Class, 2020-2026
Table 3.3 Forecasts for the World Sales ($m) of Antibacterial Classes, 2009-2017
Table 3.4 Forecasts for the World Sales ($m) of Antibacterial Classes, 2020-2026
Table 4.1 World Sales ($m) Forecast for the Cephalosporins, 2011-2019
Table 4.2 World Sales ($m) Forecast for the Cephalosporins, 2020-2026
Table 5.1 World Sales ($m) Forecast for the Penicillins, 2011-2019
Table 5.2 World Sales ($m) Forecast for the Penicillins, 2020-2026
Table 6.1 World Sales ($m) Forecast for the Fluoroquinolones, 2009-2019
Table 6.2 World Sales ($m) Forecast for the Fluoroquinolones, 2020-2026
Table 7.1 World Sales ($m) Forecast for the Macrolides, 2009-2019
Table 7.2 World Sales ($m) Forecast for the Macrolides, 2020-2026
Table 8.1 World Sales ($m) Forecast for the Carbapenems, 2009-2019
Table 8.2 World Sales ($m) Forecast for the Carbapenems, 2020-2026
Table 9.1 Sales ($m) of Antibacterial Agents by Country, 2010
Table 9.2 Antibacterial Sales ($m) Forecasts for the Leading National Markets, 2009-2018
Table 9.3 Antibacterial Sales ($m) Forecasts for the Leading National Markets, 2019-2026
Table 10.1 SWOT Analysis of the Market, 2011
Table 12.1 Prominent Pipeline Agents for Antibacterial Uses, 2010
Table 13.1 World Sales ($m) of Leading Antibacterial Agents by Drug Class, from 2011
Table 13.2 Forecast Sales ($m) for Leading Antibacterial Agents, 2011 and 2026

List of Figures

Figure 3.1 Antibacterial Market Shares ($m, %) for Leading Agents by Drug Class, 2011
Figure 3.2 Antibacterial Market Shares ($m, %) for Leading Agents by Drug Class, 2026
Figure 3.3 World Sales ($m) Forecast for Antibacterial Classes, 2009-2017
Figure 3.4 World Sales ($m) Forecast for Antibacterial Classes, 2018-2026
Figure 3.5 World Sales ($m) Forecast for the Leading Antibacterial Agents, 2009-2026
Figure 3.6 Sales ($m) Forecast for the World Antibacterials Market, 2009-2026
Figure 4.1 World Sales ($m) Forecast for Rocephin, 2009-2026
Figure 4.2 World Sales ($m) Forecast for Zinnat, 2009-2026
Figure 4.3 World Sales ($m) Forecast for Flomox, 2009-2026
Figure 4.4 World Sales ($m) Forecast for Meiact, 2009-2026
Figure 4.5 World Sales ($m) Forecast for Fortum, 2009-2026
Figure 5.1 World Sales ($m) Forecast for Tazocin, 2009-2026
Figure 5.2 World Sales ($m) Forecast for Augmentin, 2009-2026
Figure 5.3 World Sales ($m) Forecast for Unsayn, 2009-2026
Figure 6.1 World Sales ($m) Forecast for Levaquin, 2009-2026
Figure 6.2 World Sales ($m) Forecast for Avelox, 2009-2026
Figure 6.3 World Sales ($m) Forecast for Cravit, 2009-2026
Figure 7.1 World Sales ($m) Forecast for Klacid, 2009-2026
Figure 7.2 World Sales ($m) Forecast for Zithromax, 2009-2026
Figure 7.3 World Sales ($m) Forecast for Dalacin C, 2009-2026
Figure 8.1 World Sales ($m) Forecast for Merrem, 2009-2026
Figure 8.2 World Sales ($m) Forecast for Zienam, 2009-2026
Figure 8.3 World Sales ($m) Forecast for Invanz, 2009-2026
Figure 9.1 Sales ($m) for Leading Countries in the Antibacterials Market, 2010
Figure 9.2 Shares (%) of the World Antibacterial Drug Market by Country, 2010
Figure 9.3 Shares (%) of the World Antibacterial Drug Market by Country, 2026
Figure 9.4 US, China, Japan and India: Antibacterial Market Forecasts ($m), 2009-2026
Figure 9.5 Leading European Antibacterial Market Forecasts ($m), 2009-2026
Figure 9.6 Brazil: Antibacterial Market Forecast ($m), 2009-2026
Figure 13.1 World Sales ($m) of Leading Antibacterial Agents by Drug Class, 2011-2026
 
Companies Listed

Abbott Laboratories
Alfred E. Tiefenbacher 
Alliance for the Prudent Use of Antibacterials
American Pharmaceutical Partners
Andrx Corporation
Apotex
Arpida
AstraZeneca
Basilea Pharmaceutica
Bayer
Bedford Laboratories
Ben Venue Laboratories 
Boryung
Chinese Ministry of Health
Daiichi Sankyo
Dr. Reddy's Laboratories
Durata Therapeutics
Eon Laboratories Manufacturing
European Medicines Agency (EMA)
Food and Drug Administration (US FDA) 
Forest Laboratories
GlaxoSmithKline
Hospira
Ivax Pharmaceuticals
Johnson & Johnson
Leeds University, UK
Lupin Pharmaceuticals
Meiji Seika
Merck & Co.
Mitsubishi Tanabe Pharma Corporation
Mutual Pharmaceutical
Mylan
Nanotherapeutics
Novartis
Novexel
Omnicef
Optimer Pharmaceuticals
Orchid Pharma
Oscient Pharmaceuticals
Pfizer
Pliva
Ranbaxy Laboratories
Roche
Sandoz
Sanofi-Aventis
Schering-Plough
Shionogi & Co.
Sumitomo Pharmaceuticals
Takeda Pharmaceutical Company
TAP Holdings
Teva Pharmaceuticals
United Nations
University of Texas Health Science Center, San Antonio, US
Vicuron Pharmaceuticals
Watson Pharmaceuticals
Wayne State University, US
World Health Organisation (WHO)
Wyeth (now part of Pfizer)

+44 20 8816 8548

Ask a question about Antibacterial Drugs: Commercial Prospects 2011-2026

Enter the characters you see in the picture below
Captcha